Supplementary Figure S1: Silibinin inhibits growth of pancreatic cancer cell lines and induces apoptosis. A. AsPC-1 B. BxPC-3 C. MIAPaCa-2 and PANC-1 cells were treated with different doses of silibinin for 72 h and cell survival was determined by MTT assay. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001.
Supplementary Figure S2: Silibinin reduces blood glucose level and improves glucose tolerance. A. Blood glucose level of mice were measured after overnight fasting by using glucose test strips and glucometer. B. Intraperitoneal glucose tolerance tests in mice were performed as described in methods section. Representative average glucose levels at different time points are plotted. *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001.
Supplementary Figure S3: Silbinin inhibits TNF-α and IL-6 expression. S2-013 cells were treated with 100 μM of silbinin for 12 h and total RNA was isolated. Relative mRNA levels of A. TNF-α and B. IL-6 were determined by performing qRT-PCR. Actin was used as an internal control. Total RNA was isolated from primary tumors from control and silbinin-treated mice and relative mRNA levels of C. TNF-α and D. IL-6 were determined by performing qRT-PCR. Actin was utilized as internal control. Values represented are mean ± SEM. *p < 0.05.